The male to female (M:F) ratio for OTRs with melanoma was 14:1, indicating a higher predominance of melanoma among men with organ transplants than men in the total melanoma population (M:F 1.6:1). 4 However, the predominance of melanoma among male OTRs is probably a reflection of the high proportion of men in the transplant population itself. 5 The time from transplant to melanoma diagnosis varied greatly ( from 1 month to about 25.75 years). Six patients had metastatic disease present at diagnosis or at later time points; median time to stage IV disease was 18.5 months, and 5 of the 6 patients received targeted therapy. All patients underwent wide local excision and sentinel lymph node biopsy as clinically indicated and were imaged per National Comprehensive Cancer Network guidelines.
Fifteen patients were on calcineurin inhibitors, and 2 of the 15 were changed to sirolimus. The 5 patients who had metastases after the advent of Food and Drug Administrationeapproved targeted therapies and checkpoint inhibitors are detailed in Table I . Of these 5 patients, 1 received targeted therapy only (dabrafenib and trametinib) and died from melanoma progression. The remainder received checkpoint inhibitors, either as initial therapy or following BRAF inhibitor therapy. Two of these patients had a partial response to the therapy, although 1 of the renal OTRs experienced graft rejection after taking ipilimumab followed by pembrolizumab. This occurrence of graft rejection in a patient taking immune modulators is consistent with an earlier report of renal graft rejection following antiePD-1 therapy in a patient with metastatic cutaneous squamous cell carcinoma. 6 Blockade of CTLA-4 and PD-1 increases the activation of T cells, not only against malignant cells, but also other cells expressing foreign antigens such as kidney allograft donor antigens. One renal OTR with BRAF V600Eemutated melanoma progressed on dual kinase treatment and single agent antiePD-1 ( pembrolizumab) and is currently being treated with nivolumab and talimogene laherparepvec (a herpes simplex type 1ederived oncolytic intralesional immunotherapy) to subcutaneous metastases. Talimogene laherparepvec has not previously been reported among OTRs as a single agent therapy or in conjunction with checkpoint inhibitors.
In summary, the use of checkpoint inhibitors in OTRs with metastatic melanoma should be considered (Table II) . However, special considerations should be given for the use of checkpoint inhibitors in patients with certain types of transplanted organs (such as liver) because of the potential for graft rejection. We also propose that multiple institutions report the use of these agents; this practice would be more effective at determining the drug efficacy and risk among OTRs. Interrater reliability for histopathologic diagnosis of keratinocyte carcinomas
To the Editor: Treatment of keratinocyte carcinomas (KCs, ie, basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]) often depends on histopathologic diagnosis, which might be unreliable. We sought to achieve high diagnostic reliability among dermatopathologists through measures such as meeting quarterly to review cases and discuss diagnostic criteria. Participants were enrolled in the Veterans Affairs (VA) Keratinocyte Carcinoma Chemoprevention Trial.
1 Biopsied lesions were read by local pathologists, and biopsies acquired from the face and ears were sent for central review by up to 3 board-certified dermatopathologists. Diagnostic categories included BCC (including histologic subtype), SCC (including invasive SCC and SCC in situ), actinic keratosis (AK), and other (Table I) .
We used kappa () and percent agreement to calculate the interrater reliability of diagnoses. The standardized values of kappa typically range from 0 to 1, with 0 depicting agreement expected by random chance and 1 representing perfect agreement. 
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